What do Cochrane systematic reviews say about interventions for age-related macular degeneration?
Vania MozeticRafael Leite PachecoCarolina de Oliveira Cruz LatorracaFernanda Chin Yu Ogasawara LeeJoão Victor Borges GomesRachel RieraPublished in: Sao Paulo medical journal = Revista paulista de medicina (2020)
The Cochrane systematic reviews found evidence that use of bevacizumab, ranibizumab, pegaptanib, laser photocoagulation, photodynamic therapy and multivitamin compounds may present some benefits for treating AMD. There was insufficient evidence for supporting the use of macular translocation, submacular surgery, steroid implantation, radiotherapy, intravitreal aflibercept, interferon alfa, statins or omega-3 fatty acids for treating AMD; or the use of multivitamin antioxidant vitamins or mineral supplementation for preventing AMD. Future randomized controlled trials are imperative to reduce the uncertainty in several clinical questions regarding AMD.
Keyphrases
- age related macular degeneration
- photodynamic therapy
- systematic review
- meta analyses
- fatty acid
- randomized controlled trial
- minimally invasive
- early stage
- diabetic retinopathy
- cardiovascular disease
- physical activity
- radiation therapy
- oxidative stress
- coronary artery bypass
- dendritic cells
- type diabetes
- squamous cell carcinoma
- current status
- radiation induced
- anti inflammatory
- replacement therapy